DE60002484D1 - Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält - Google Patents

Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält

Info

Publication number
DE60002484D1
DE60002484D1 DE60002484T DE60002484T DE60002484D1 DE 60002484 D1 DE60002484 D1 DE 60002484D1 DE 60002484 T DE60002484 T DE 60002484T DE 60002484 T DE60002484 T DE 60002484T DE 60002484 D1 DE60002484 D1 DE 60002484D1
Authority
DE
Germany
Prior art keywords
physiologically acceptable
intestinal absorption
amylase inhibitor
composition
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60002484T
Other languages
English (en)
Other versions
DE60002484T2 (de
Inventor
Nils Christian Mortensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MED EQ AS SENTRUM
Original Assignee
MED EQ AS SENTRUM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MED EQ AS SENTRUM filed Critical MED EQ AS SENTRUM
Publication of DE60002484D1 publication Critical patent/DE60002484D1/de
Application granted granted Critical
Publication of DE60002484T2 publication Critical patent/DE60002484T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE60002484T 1999-09-08 2000-09-08 Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält Expired - Fee Related DE60002484T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9921229 1999-09-08
GBGB9921229.2A GB9921229D0 (en) 1999-09-08 1999-09-08 Compositions
PCT/GB2000/003472 WO2001017369A1 (en) 1999-09-08 2000-09-08 Composition comprising an alpha-amylase inhibitor and at least one physiologically acceptable compound capable of reducing intestinal absorption of 'fast sugars'

Publications (2)

Publication Number Publication Date
DE60002484D1 true DE60002484D1 (de) 2003-06-05
DE60002484T2 DE60002484T2 (de) 2004-03-18

Family

ID=10860574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60002484T Expired - Fee Related DE60002484T2 (de) 1999-09-08 2000-09-08 Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält

Country Status (14)

Country Link
EP (1) EP1213972B1 (de)
JP (1) JP2003508467A (de)
KR (1) KR100594520B1 (de)
AT (1) ATE238689T1 (de)
AU (1) AU777044B2 (de)
CA (1) CA2383720A1 (de)
DE (1) DE60002484T2 (de)
DK (1) DK1213972T3 (de)
ES (1) ES2199174T3 (de)
GB (2) GB9921229D0 (de)
NO (1) NO314922B1 (de)
NZ (1) NZ518167A (de)
PT (1) PT1213972E (de)
WO (1) WO2001017369A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US6797287B2 (en) 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
US7108869B2 (en) 2002-11-07 2006-09-19 Access Business Group International Llc Nutritional supplement containing alpha-glucosidase and alpha-amylase inhibitors
ITMI20030391A1 (it) * 2003-03-04 2004-09-05 S I I T S R L Servizio Internaz Ionale Imballa Formulazioni anticarie a base di faseolamina.
JP5285852B2 (ja) * 2006-12-28 2013-09-11 株式会社ファンケル Ｄｆａｉｉｉの製造方法及びｄｆａｉｉｉ高含有植物エキス
WO2009112054A1 (en) * 2008-03-10 2009-09-17 Phf S.A. High bioavailability formulation of mangosteen and manufacturing process thereof
CN102292093B (zh) * 2009-02-02 2015-01-28 莱拉营养食品有限公司 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物
JP2011079752A (ja) * 2009-10-05 2011-04-21 Kracie Home Products Ltd 膵リパーゼ阻害剤並びにそれを含有する飲食品組成物及び医薬品組成物
CN103478738B (zh) * 2013-09-17 2016-02-10 深圳太太药业有限公司 一种具有减肥塑身及体重管理作用的组合物
EP3193899A1 (de) * 2014-09-19 2017-07-26 Nestec S.A. Verfahren und formulierungen zur senkung der resorption der kohlenhydrate in ein haustier
CN106036342A (zh) * 2016-06-14 2016-10-26 安徽平唐微食疗科技有限公司 适合于糖尿病人群食用的膳食补充固体饮料及其制备方法
IT201700078389A1 (it) * 2017-07-13 2019-01-13 Mv Medical Solutions Composizione utile nella prevenzione o trattamento degli stati di malassorbimento secondari a chirurgia bariatrica in soggetti obesi.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010258A (en) * 1974-03-15 1977-03-01 Ajinomoto Co., Inc. Microbial amylase inhibitor and preparation thereof with the use of streptomyces diasticus var. amylostaticus
JP2757405B2 (ja) * 1988-12-09 1998-05-25 日清製粉株式会社 小麦から得られるα−アミラーゼインヒビターを含有するダイエット剤
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
ATE271392T1 (de) * 1999-01-22 2004-08-15 Hunza Di Pistolesi Elvira & C Lipoproteinkomplexe und zusammensetzungen, die diese enthalten

Also Published As

Publication number Publication date
GB2364498A (en) 2002-01-30
CA2383720A1 (en) 2001-03-15
AU7026900A (en) 2001-04-10
GB0127158D0 (en) 2002-01-02
GB9921229D0 (en) 1999-11-10
ATE238689T1 (de) 2003-05-15
WO2001017369A1 (en) 2001-03-15
KR20020045605A (ko) 2002-06-19
PT1213972E (pt) 2003-09-30
AU777044B2 (en) 2004-09-30
DK1213972T3 (da) 2003-08-18
EP1213972B1 (de) 2003-05-02
NO20021160D0 (no) 2002-03-08
DE60002484T2 (de) 2004-03-18
NO20021160L (no) 2002-03-27
EP1213972A1 (de) 2002-06-19
JP2003508467A (ja) 2003-03-04
NO314922B1 (no) 2003-06-16
NZ518167A (en) 2003-03-28
KR100594520B1 (ko) 2006-07-19
ES2199174T3 (es) 2004-02-16

Similar Documents

Publication Publication Date Title
DE60002484D1 (de) Zusammensetzung die einen alpha-amylase inhibitor und mindestens eine physiologisch akzeptabele komponente, der die intestinale absorption von "fast sugars" reduzieren kann, enthält
DK0682664T3 (da) Forbindelser med både potent calciumantagonist og antioxiderende aktivitet og anvendelse deraf som cytobeskyttende midler
DE69226624T2 (de) Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SG152255A1 (en) Compositions comprising nebivolol
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CO5631443A2 (es) Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
TR200000785T2 (tr) Yeni NPY antagonistleri.
SG162734A1 (en) Compositions comprising nebivolol
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
DE60031421D1 (de) Pflanzenextrakt-mischungen (cissus, vernonia, brillantaisia) und ihre verwendungen
DE60228722D1 (de) Zusammensetzung und ihre verwendungszwecke zur bekämpfung von kater
AU3109502A (en) Method and composition for the treatment of diabetic neuropathy
NO20040153L (no) Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO990813L (no) Forlegering for kornforfining av aluminiumslegeringer
EP1068868A3 (de) Synergistischer Zusammensetzung, der Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeneration
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
NO20065142L (no) Trisubstituerte ureaer som cytokininhibitorer
ES8407031A1 (es) "procedimiento para la preparacion de n-(2-metil--5-cloro-fenil)-n-metoxiacetil-3-amino-1,3-oxazilidin-urea"
WO2023244996A3 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee